ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers

MLA

Jing, Na, et al. “ADORA2A-Driven Proline Synthesis Triggers Epigenetic Reprogramming in Neuroendocrine Prostate and Lung Cancers.” Journal of Clinical Investigation, vol. 133, no. 24, Dec. 2023. EBSCOhost, https://doi.org/10.1172/JCI168670.

APA

Jing, N., Zhang, K., Chen, X., Liu, K., Wang, J., Xiao, L., Zhang, W., Ma, P., Xu, P., Cheng, C., Wang, D., Zhao, H., He, Y., Ji, Z., Xin, Z., Sun, Y., Zhang, Y., Bao, W., Gong, Y., … Zhu, H. H. (2023). ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers. Journal of Clinical Investigation, 133(24). https://doi.org/10.1172/JCI168670

Chicago

Jing, Na, Kai Zhang, Xinyu Chen, Kaiyuan Liu, Jinming Wang, Lingling Xiao, Wentian Zhang, et al. 2023. “ADORA2A-Driven Proline Synthesis Triggers Epigenetic Reprogramming in Neuroendocrine Prostate and Lung Cancers.” Journal of Clinical Investigation 133 (24). doi:10.1172/JCI168670.